← All trials
NCT04770272
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2021
- Primary completion
- Aug 1, 2023
- Completion date
- Jan 1, 2026
- First posted
- Feb 25, 2021
- Last posted
- Mar 3, 2021
- Enrollment
- 458
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Palleos Healthcare GmbHLead sponsor
- RocheCollaborator
- University of Duisburg-EssenCollaborator
- Palleos Healthcare GmbHStudy director
- University of Erlangen-NurembergCollaborator
- Marienhospital StuttgartOverall official - principal investigator
- Phaon Scientific GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.